Kelsey Goodwin analyst PIPER SANDLER

Currently out of the existing stock ratings of Kelsey Goodwin, 38 are a BUY (95%), 2 are a HOLD (5%).

Kelsey Goodwin

Work Performance Price Targets & Ratings Chart

Analyst Kelsey Goodwin, currently employed at PIPER SANDLER, has had 47.62% of price targets met with an average potential upside of 26.15%, reached in 72 days on average.

Kelsey Goodwin has documented 75 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RVMD, at 04-Nov-2026.

Wall Street Analyst Kelsey Goodwin

Analyst best performing recommendations are on NUVL.
The best stock recommendation documented was for NUVL on 9/16/2024. The price target of $105 was fulfilled within 1 day with a profit of $7.17 (6.39%), with a performance score of 63.92.

Average potential price target upside

ACLX Arcellx BCAX Bicara Therapeutics BDTX Black Diamond Therapeutics CGON CG Oncology DAY Dayforce ERAS IPSC JANX NUVL RVMD SMMT Summit Therapeutics PLC TNGX URGN TSVT

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 31-Oct-2022

$115

$-0.07 (-0.06%)

8 months 23 days ago
(26-Feb-2026)

2/2 (100%)

$1.12 (0.98%)

110

Buy Since 01-Mar-2022

$115

$-0.07 (-0.06%)

$39

8 months 25 days ago
(24-Feb-2026)

9/9 (100%)

$1.25 (1.10%)

279

Buy Since 18-May-2023

$120

$4.93 (4.28%)

$136

8 months 25 days ago
(24-Feb-2026)

4/6 (66.67%)

$6.25 (5.49%)

192

Buy Since 11-Dec-2025

$115

$-0.07 (-0.06%)

$127

8 months 25 days ago
(24-Feb-2026)

1/5 (20%)

$1.25 (1.10%)

50

Buy Since 07-Jan-2026

$115

$-0.07 (-0.06%)

$100

8 months 25 days ago
(24-Feb-2026)

2/2 (100%)

$1.25 (1.10%)

49

Show more analysts

Please expand the browser size to see the chart

Which stock is Kelsey Goodwin most bullish on?

Potential upside of $59.31 has been obtained for RVMD

Which stock is Kelsey Goodwin most reserved on?

Potential downside of $0.22 has been obtained for CGON (CG ONCOLOGY)

What Year was the first public recommendation made by Kelsey Goodwin?

On 2022
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?